Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $1.5 million.

  • Fulcrum Therapeutics' Change in Accured Expenses rose 1429.67% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 46866.54%. This contributed to the annual value of -$1.0 million for FY2024, which is 2509.09% down from last year.
  • Fulcrum Therapeutics' Change in Accured Expenses amounted to $1.5 million in Q3 2025, which was up 1429.67% from $587000.0 recorded in Q2 2025.
  • Fulcrum Therapeutics' Change in Accured Expenses' 5-year high stood at $5.8 million during Q2 2022, with a 5-year trough of -$4.5 million in Q3 2022.
  • Over the past 5 years, Fulcrum Therapeutics' median Change in Accured Expenses value was $587000.0 (recorded in 2025), while the average stood at -$32526.3.
  • Examining YoY changes over the last 5 years, Fulcrum Therapeutics' Change in Accured Expenses showed a top increase of 231300.0% in 2021 and a maximum decrease of 211538.46% in 2021.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Change in Accured Expenses stood at -$795000.0 in 2021, then skyrocketed by 296.48% to $1.6 million in 2022, then plummeted by 41.81% to $909000.0 in 2023, then plummeted by 170.41% to -$640000.0 in 2024, then skyrocketed by 332.34% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $587000.0 for Q2 2025, and -$3.3 million during Q1 2025.